DK2041161T3 - Chirale med phosphonsyreestere eller phosphonsyrer substituerede forbindelser - Google Patents
Chirale med phosphonsyreestere eller phosphonsyrer substituerede forbindelserInfo
- Publication number
- DK2041161T3 DK2041161T3 DK07786231.6T DK07786231T DK2041161T3 DK 2041161 T3 DK2041161 T3 DK 2041161T3 DK 07786231 T DK07786231 T DK 07786231T DK 2041161 T3 DK2041161 T3 DK 2041161T3
- Authority
- DK
- Denmark
- Prior art keywords
- phosphonic
- chiral
- phosphonic acid
- acid esters
- substituted compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003008 phosphonic acid esters Chemical group 0.000 title 1
- 150000003009 phosphonic acids Chemical group 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001918 phosphonic acid ester group Chemical group 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006034319A DE102006034319A1 (de) | 2006-07-21 | 2006-07-21 | Chirale mit Phosponsäurester- oder Phosphonsäure- substituierte Verbindungen |
| PCT/EP2007/006483 WO2008009470A1 (de) | 2006-07-21 | 2007-07-20 | Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2041161T3 true DK2041161T3 (da) | 2011-07-18 |
Family
ID=38606655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07786231.6T DK2041161T3 (da) | 2006-07-21 | 2007-07-20 | Chirale med phosphonsyreestere eller phosphonsyrer substituerede forbindelser |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100022478A1 (da) |
| EP (1) | EP2041161B1 (da) |
| JP (1) | JP5270543B2 (da) |
| CN (1) | CN101495505A (da) |
| AT (1) | ATE509945T1 (da) |
| AU (1) | AU2007276381B2 (da) |
| CA (1) | CA2658633C (da) |
| DE (1) | DE102006034319A1 (da) |
| DK (1) | DK2041161T3 (da) |
| ES (1) | ES2361633T3 (da) |
| WO (1) | WO2008009470A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006050091A1 (de) * | 2006-10-24 | 2008-09-11 | Ugichem Gesellschaft für Organische Chemie mbH | Verfahren zur selektiven Lokalisierung von Wirkstoffen an und in Mitochondrien und entsprechende Wirkstoffe |
| DE102014007158A1 (de) * | 2014-05-16 | 2015-11-19 | Ugichem Gmbh | Neue Peptid-Nukleinsäuren-Monomere und -Oligomere |
| KR102080287B1 (ko) | 2016-12-06 | 2020-02-21 | 주식회사 엘지화학 | (메트)아크릴산의 회수 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| GB2289677A (en) * | 1993-12-06 | 1995-11-29 | Pna Diagnostics As | Labelling of nucleic acid analogue-peptide chimerae |
| DE4408528A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung |
| CA2261566A1 (en) | 1996-07-24 | 1998-01-29 | Buchardt, Dorte | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| DE19909373A1 (de) * | 1999-03-03 | 2000-10-05 | Ugichem | Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung |
-
2006
- 2006-07-21 DE DE102006034319A patent/DE102006034319A1/de not_active Withdrawn
-
2007
- 2007-07-20 WO PCT/EP2007/006483 patent/WO2008009470A1/de active Application Filing
- 2007-07-20 AU AU2007276381A patent/AU2007276381B2/en active Active
- 2007-07-20 CA CA2658633A patent/CA2658633C/en active Active
- 2007-07-20 EP EP07786231A patent/EP2041161B1/de active Active
- 2007-07-20 CN CNA2007800277493A patent/CN101495505A/zh active Pending
- 2007-07-20 AT AT07786231T patent/ATE509945T1/de active
- 2007-07-20 JP JP2009521152A patent/JP5270543B2/ja active Active
- 2007-07-20 US US12/374,440 patent/US20100022478A1/en not_active Abandoned
- 2007-07-20 DK DK07786231.6T patent/DK2041161T3/da active
- 2007-07-20 ES ES07786231T patent/ES2361633T3/es active Active
-
2012
- 2012-06-19 US US13/527,217 patent/US9951093B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007276381B2 (en) | 2012-07-12 |
| ATE509945T1 (de) | 2011-06-15 |
| US20130131019A1 (en) | 2013-05-23 |
| JP2009544776A (ja) | 2009-12-17 |
| CA2658633C (en) | 2015-02-24 |
| WO2008009470A1 (de) | 2008-01-24 |
| AU2007276381A1 (en) | 2008-01-24 |
| CA2658633A1 (en) | 2008-01-24 |
| US9951093B2 (en) | 2018-04-24 |
| DE102006034319A1 (de) | 2008-01-31 |
| EP2041161A1 (de) | 2009-04-01 |
| ES2361633T3 (es) | 2011-06-20 |
| US20100022478A1 (en) | 2010-01-28 |
| CN101495505A (zh) | 2009-07-29 |
| JP5270543B2 (ja) | 2013-08-21 |
| EP2041161B1 (de) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
| UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
| EA201691029A1 (ru) | Кристаллические формы аналогов противовирусного соединения софосбувира | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| DE602005017027D1 (de) | Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure | |
| IN2012DN00721A (da) | ||
| EP4279610A3 (en) | Ribonucleic acid purification | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| DE602007007666D1 (de) | Verfahren zur herstellung von nebivolol | |
| MA32400B1 (fr) | Isoquinoléines et isoquinolinones substituées en tant qu'inhibiteurs de rho-kinase | |
| IN2012DN00801A (da) | ||
| WO2008067219A3 (en) | Quinazolinone modulators of tgr5 | |
| WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
| ATE537136T1 (de) | Neues verfahren zur herstellung von säurechloriden | |
| CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
| GEP20186885B (en) | Novel compounds | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| WO2009114475A3 (en) | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use | |
| ATE533774T1 (de) | Neuartige nukleosidanaloge zur behandlung von virusinfektionen | |
| MX339361B (es) | Derivados de alternano. | |
| DK2041161T3 (da) | Chirale med phosphonsyreestere eller phosphonsyrer substituerede forbindelser | |
| EA201300440A1 (ru) | Способ получения (3s,3s') 4,4'-дисульфандиилбис(3-аминобутан-1-сульфокислоты) | |
| DE502005009157D1 (de) | Verfahren zur herstellung von alkenylbernsteinsäureanhydriden | |
| DE502005009501D1 (de) | Verfahren zur herstellung von candesartan |